ArticleAdvances in therapy2022
Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab.
Article in Advances in therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 67 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)
A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy (ZONDA)
Who cites it
67 citing papers in PubMed, 1 synthesis or guideline pooled it, 131 citations in OpenAlex.
- Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses.The European respiratory journal · 2024Guideline
- Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN.Advances in therapy · 2026Trial
- Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.The European respiratory journal · 2024Trial
- Predictors of response to mepolizumab for severe asthma: a REDES study post hoc analysis.BMJ open · 2026Observational
- Review
- Is Asthma Remission a New Achievable Goal? A Review of the Current Drug-Related Evidence and Predictors.Allergy · 2026Review
- Achieving clinical remission in moderate-to-severe asthma using inhaled triple therapy.ERJ open research · 2026Article
- Allergen Immunotherapy and Possible Clinical Remission: Toward a Disease-Modifying Paradigm in Allergic Disorders.Biomedicines · 2026Review
- Review
- Consensus of Korean Asthma Study Group on Definition of Clinical Remission in Severe Asthma: A Modified Delphi Study.Tuberculosis and respiratory diseases · 2026Article
- Baseline Composite Score for 12-Month Clinical Remission in Biologic-Treated Severe Asthma: Development of the Base4Score.Biomedicines · 2026Article
- Predicting clinical remission in biologic-treated severe asthma: development of a practical scoring system from a Japanese multicentre study.BMJ open respiratory research · 2026Article
- Early and Sustained Asthma Control and Remission in Real-World Patients With Severe Eosinophilic Asthma Treated With Benralizumab: XALOC-2.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Observational
- Multidomain clinical and biological remission with tezepelumab in severe asthma: a 12-month multicentre real-world study.Respiratory research · 2026Observational
- Comparative efficacy of mepolizumab and benralizumab in severe eosinophilic asthma: a retrospective cohort study.BMC pulmonary medicine · 2026Article
- Challenges in Evaluating Clinical Remission in Severe Asthma: Insights from the Mayo Clinic.Advances in therapy · 2026Article
- Clinical Remission in Patients with Severe Eosinophilic Asthma - A Single-Arm Observational Study with Benralizumab.Journal of asthma and allergy · 2026Article
- Evaluation of the concordance of asthma remission definitions according to international guidelines in a cohort of patients treated with monoclonal antibodies for severe asthma.Frontiers in pharmacology · 2026Article
- Predictive Factors And Treatments Associated with Clinical Remission in Severe Eosinophilic Asthma.Journal of inflammation research · 2026Review
- Understanding disease burden, challenges in current treatment strategies and call for action for management of severe asthma in Asia: a position statement from Asian respiratory experts.Frontiers in allergy · 2026Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionConsensus definitions for clinical remission and super-response were recently established for severe asthma. Benralizumab is an interleukin-5 (IL-5) receptor α-directed monoclonal antibody for severe, uncontrolled asthma; efficacy and safety were demonstrated in previous pivotal phase 3 trials (SIROCCO, CALIMA, ZONDA). This analysis applied a composite remission definition to characterize individual responses to benralizumab after 6 and 12 months.
methodsIn previous phase 3 studies, eligible patients were those with severe, uncontrolled asthma receiving medium- or high-dosage inhaled corticosteroids plus long-acting β
resultsOverall, 609 patients (N = 301 and N = 308) and 586 patients (N = 293 and N = 293) receiving benralizumab in SIROCCO and CALIMA were included at 6 and 12 months, respectively; 40 ZONDA patients were included after 6 months. In SIROCCO/CALIMA, similar to 6-month findings, approx. 83% and approx. 49% receiving benralizumab, and 77% and 37% on placebo achieved ≥ 2 and ≥ 3 remission components after 12 months; 14.5% (85/586) on benralizumab and 7.7% (48/620) on placebo achieved clinical remission at 12 months. Among ZONDA patients, 75% and approx. 48% on benralizumab and 35% and 20% on placebo achieved ≥ 2 and ≥ 3 remission components at 6 months, respectively; 22.5% (9/40) on benralizumab and 7.5% on placebo achieved clinical remission.
conclusionsThis analysis demonstrates clinical remission is achievable by targeting the underlying drivers of inflammation. Precision medicines can help shift treatment paradigms toward treat-to-target, with clinical remission as the ultimate therapeutic goal in severe asthma. CLINICAL
trial registrationSIROCCO (NCT01928771); CALIMA (NCT01914757); ZONDA (NCT02075255).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.